questionsmedicales.fr
Facteurs biologiques
Antigènes
Antigènes de surface
Molécules d'adhérence cellulaire
Lectine-2 de type Ig liant l'acide sialique
Lectine-2 de type Ig liant l'acide sialique : Questions médicales fréquentes
Termes MeSH sélectionnés :
Early Detection of Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lectine-2 de type Ig liant l'acide sialique : Questions médicales les plus fréquentes",
"headline": "Lectine-2 de type Ig liant l'acide sialique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lectine-2 de type Ig liant l'acide sialique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lectine-2 de type Ig liant l'acide sialique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Molécules d'adhérence cellulaire",
"url": "https://questionsmedicales.fr/mesh/D015815",
"about": {
"@type": "MedicalCondition",
"name": "Molécules d'adhérence cellulaire",
"code": {
"@type": "MedicalCode",
"code": "D015815",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.301.350"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lectine-2 de type Ig liant l'acide sialique",
"alternateName": "Sialic Acid Binding Ig-like Lectin 2",
"code": {
"@type": "MedicalCode",
"code": "D051918",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ken Kitajima",
"url": "https://questionsmedicales.fr/author/Ken%20Kitajima",
"affiliation": {
"@type": "Organization",
"name": "Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan."
}
},
{
"@type": "Person",
"name": "Chihiro Sato",
"url": "https://questionsmedicales.fr/author/Chihiro%20Sato",
"affiliation": {
"@type": "Organization",
"name": "Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan. chi@agr.nagoya-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Thomas Haselhorst",
"url": "https://questionsmedicales.fr/author/Thomas%20Haselhorst",
"affiliation": {
"@type": "Organization",
"name": "Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Dinglong Yang",
"url": "https://questionsmedicales.fr/author/Dinglong%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Muping Coastal Environment Research Station, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, PR China; Center for Ocean Mega-science, Chinese Academy of Sciences, Qingdao, Shandong, 266071, PR China. Electronic address: dlyang@yic.ac.cn."
}
},
{
"@type": "Person",
"name": "Takeo Tatsuta",
"url": "https://questionsmedicales.fr/author/Takeo%20Tatsuta",
"affiliation": {
"@type": "Organization",
"name": "Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37511475",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241411715"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.",
"datePublished": "2023-03-07",
"url": "https://questionsmedicales.fr/article/36894035",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.gastro.2023.02.044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36855007",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12350-023-03202-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimal age to stop prostate cancer screening and early detection.",
"datePublished": "2023-08-19",
"url": "https://questionsmedicales.fr/article/37598870",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcpo.2023.100443"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer.",
"datePublished": "2022-10-03",
"url": "https://questionsmedicales.fr/article/36121650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijc.34298"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes de surface",
"item": "https://questionsmedicales.fr/mesh/D000954"
},
{
"@type": "ListItem",
"position": 5,
"name": "Molécules d'adhérence cellulaire",
"item": "https://questionsmedicales.fr/mesh/D015815"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lectine-2 de type Ig liant l'acide sialique",
"item": "https://questionsmedicales.fr/mesh/D051918"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lectine-2 de type Ig liant l'acide sialique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Comment diagnostiquer une dysfonction de Siglec-2 ?\nQuels tests sont utilisés pour évaluer Siglec-2 ?\nY a-t-il des biomarqueurs associés à Siglec-2 ?\nQuels symptômes peuvent indiquer un problème avec Siglec-2 ?\nComment évaluer l'expression de Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels symptômes sont liés à une altération de Siglec-2 ?\nLa fatigue est-elle un symptôme associé à Siglec-2 ?\nDes douleurs articulaires peuvent-elles être liées à Siglec-2 ?\nLes allergies sont-elles influencées par Siglec-2 ?\nY a-t-il des signes cutanés associés à Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Comment prévenir les dysfonctionnements de Siglec-2 ?\nL'alimentation influence-t-elle Siglec-2 ?\nLe stress affecte-t-il Siglec-2 ?\nLes vaccinations aident-elles Siglec-2 ?\nY a-t-il des exercices bénéfiques pour Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels traitements ciblent Siglec-2 ?\nLes anti-inflammatoires aident-ils avec Siglec-2 ?\nY a-t-il des traitements expérimentaux pour Siglec-2 ?\nComment la thérapie génique peut-elle aider Siglec-2 ?\nLes probiotiques peuvent-ils influencer Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quelles complications peuvent survenir avec Siglec-2 ?\nSiglec-2 est-il lié à des cancers ?\nLes maladies cardiovasculaires sont-elles liées à Siglec-2 ?\nY a-t-il des risques neurologiques associés à Siglec-2 ?\nComment les complications de Siglec-2 affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels facteurs de risque influencent Siglec-2 ?\nLe tabagisme affecte-t-il Siglec-2 ?\nL'obésité est-elle un facteur de risque pour Siglec-2 ?\nLe diabète influence-t-il Siglec-2 ?\nLe manque de sommeil affecte-t-il Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de Siglec-2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses de cellules immunitaires peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer Siglec-2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunohistochimie et les tests de liaison des lectines sont courants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à Siglec-2 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de Siglec-2 peuvent servir de biomarqueurs dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec Siglec-2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections récurrentes ou une inflammation excessive peuvent être des signes."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'expression de Siglec-2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse par cytométrie en flux peut quantifier l'expression de Siglec-2."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une altération de Siglec-2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des infections fréquentes et des réactions inflammatoires."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme associé à Siglec-2 ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue peut survenir en raison d'une réponse immunitaire altérée."
}
},
{
"@type": "Question",
"name": "Des douleurs articulaires peuvent-elles être liées à Siglec-2 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inflammation excessive due à Siglec-2 peut provoquer des douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Les allergies sont-elles influencées par Siglec-2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Siglec-2 peut moduler les réponses allergiques et inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à Siglec-2 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent apparaître en raison d'une inflammation liée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements de Siglec-2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain et une bonne hygiène peut aider à prévenir les dysfonctionnements."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle Siglec-2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en nutriments peut soutenir la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il Siglec-2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut altérer la fonction immunitaire, y compris celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles Siglec-2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent renforcer la réponse immunitaire associée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Y a-t-il des exercices bénéfiques pour Siglec-2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la fonction immunitaire et celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent Siglec-2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies biologiques et des anticorps monoclonaux peuvent cibler Siglec-2."
}
},
{
"@type": "Question",
"name": "Les anti-inflammatoires aident-ils avec Siglec-2 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anti-inflammatoires peuvent réduire l'inflammation associée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour Siglec-2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques évaluent des traitements ciblant Siglec-2 pour diverses maladies."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique peut-elle aider Siglec-2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique pourrait corriger les dysfonctionnements liés à Siglec-2."
}
},
{
"@type": "Question",
"name": "Les probiotiques peuvent-ils influencer Siglec-2 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains probiotiques peuvent moduler l'expression de Siglec-2 et l'immunité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Siglec-2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves et des maladies auto-immunes peuvent être des complications."
}
},
{
"@type": "Question",
"name": "Siglec-2 est-il lié à des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des altérations de Siglec-2 peuvent être associées à certains types de cancers."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles liées à Siglec-2 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inflammation chronique liée à Siglec-2 peut augmenter le risque cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques neurologiques associés à Siglec-2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de Siglec-2 peuvent être impliqués dans des maladies neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les complications de Siglec-2 affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent entraîner des limitations physiques et des problèmes de santé mentale."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque influencent Siglec-2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, les maladies chroniques et le mode de vie peuvent influencer la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il Siglec-2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer la fonction immunitaire, y compris celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque pour Siglec-2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut provoquer une inflammation chronique affectant Siglec-2."
}
},
{
"@type": "Question",
"name": "Le diabète influence-t-il Siglec-2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut altérer la réponse immunitaire et la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le manque de sommeil affecte-t-il Siglec-2 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un sommeil insuffisant peut nuire à la fonction immunitaire, y compris celle de Siglec-2."
}
}
]
}
]
}
The central objective of the metamorphosis of discovery science into biomedical applications is to serve the purpose of patients and curtail the global disease burden. The journey from the discovery o...
Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improv...
The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastro...
In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) fo...
EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes....
Cancer therapy-induced cardiotoxicity is an emerging clinical and healthcare issue. Myocardial dysfunction and heart failure are mostly responsible for increased cardiovascular mortality in cancer dis...
Prostate Cancer screening should be discontinued at older ages because competing mortality risks eventually dominate the risk of Prostate Cancer and harms exceed benefits. We explored the Prostate Can...
We applied Bellman Equations to formulate the net benefits biopsy and "do nothing". Using difference between the net benefits of two alternatives, we calculated the stopping age. The cancer states wer...
Our results suggested that Prostate Cancer screening stopping ages from the patient, healthcare system, and social were 70, 68, and 68 respectively. The univariate sensitivity analysis showed that the...
Men should not be screened for Prostate Cancer beyond 70 years old, as this results in the net benefit of "do nothing" above the biopsy. Nevertheless, this finding needs to be further studied with mor...
Colorectal cancer (CRC) develops mainly from colorectal advanced adenomas (AA), which are considered precancerous lesions. Novel early diagnostic biomarkers are urgently needed to distinguish CRC and ...
The modality to detect ovarian cancer at an early stage is very limited. Early diagnosis determines the prognosis. This study aimed to develop a risk assessment tool for early detection of ovarian can...
This study was carried out as a cohort study of patients diagnosed with suspected ovarian tumors undergoing cytoreduction operation at Hasan Sadikin Hospital, Bandung, from December 2019 to September ...
In total, 115 patients included in this study. The differences were statistically significant in terms of the six variables (abdominal bloating, nausea/vomiting, decreased of appetite, fullness, menst...
Risk assessments based on ovarian cancer self-assessment unfortunately were not comparable to postoperative histopathology as a single predictor. Ten variables in ovarian cancer artificial intelligenc...
Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness o...
In this research, we harnessed the Mutation Capsule Plus (MCP) technology to profile an array of genomic characteristics from cfDNA procured from a single blood draw. This profiling encompassed DNA me...
This model was subsequently validated in another cohort comprising 89 CRC patients and 95 healthy controls. Remarkably, the model achieved an area under the curve (AUC) of 0.981 (95% confidence interv...
Our findings underscore the clinical potential of our multiomics liquid biopsy test, indicating its prospective role as a noninvasive method for early-stage CRC detection. This multiomics approach hol...
Clinical diagnostics rely heavily on the detection and quantification of cancer biomarkers. The rapid detection of cancer-specific biomarkers is of great importance in the early diagnosis of cancers a...
A cell-free DNA (cfDNA) assay would be a promising approach to early cancer diagnosis, especially for patients with dense tissues. Consistent cfDNA signatures have been observed for many carcinogens. ...
Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cir...
This is a UK-based prospective, longitudinal, diagnostic, prognostic, multicentre, non-CTIMP study. Aiming to recruit 3000 patients with liver cirrhosis without a HCC diagnosis, the Pearl cohort will ...
Ethical approval has been granted by REC and the trial is registered on ClinicalTrials.gov. The results will be published in peer-reviewed journals and presented at relevant meetings....
NCT05541601....